NPC-14

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
113	筋ジストロフィー	2

113. 筋ジストロフィー

臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-JMA-IIA00134	14/08/2013	05/08/2013	Phase II study of nonsense readthrough compound NPC-14(Arbekacin sulfate) to explore safety, tolerab ...	Phase II study of nonsense readthrough compound NPC-14(Arbekacin sulfate) to explore safety, tolerab ...	Duchenne muscular dystrophy	Intervention type:DRUG. Intervention1:NPC-14, Dose form:INJECTION, Route of administration:INTRAVENO ...	Yasuhiro Takeshima, MD, PhDHyogo College of Medicine Hospital, department of pediatrics	Not applicable	Completed	>=4 YEARS	No Limit	Male	21	Phase 2	Japan
2	NCT01918384 (ClinicalTrials.gov)	August 2013	1/8/2013	Phase II Study of NPC-14(Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenn ...	Phase II Study of Nonsense Readthrough Compound NPC-14(Arbekacin Sulfate) to Explore Safety, Tolerab ...	Muscular Dystrophy, Duchenne	Drug: NPC-14;Drug: Placebo	Kobe University	Japan Medical Association;Nobelpharma	Active, not recruiting	4 Years	N/A	Male	21	Phase 2	Japan

First Previous1Next Last